Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exscientia plc
Exscientia Business Update for First Quarter 2023
May 24, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
May 22, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
May 17, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
May 03, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
April 19, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
March 16, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
March 15, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Expansion of its Precision Oncology Pipeline
March 14, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
March 07, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Present at Upcoming Investor Conferences in March
February 22, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
February 02, 2023
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
December 06, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
November 28, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business and Financial Update for the Third Quarter 2022
November 15, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
November 14, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
November 08, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Expands Biologics Design Capability with Automated Laboratory
November 03, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
October 28, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
October 26, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Welcomes Caroline Rowland as Chief People Officer
September 08, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Second Quarter and First Half 2022
August 17, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
June 14, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for First Quarter 2022
May 25, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022
April 08, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Exscientia Business Update for Fourth Quarter and Full Year 2021
March 23, 2022
From
Exscientia plc
Via
Business Wire
Tickers
EXAI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.